HA
RPRX icon

Heartland Advisors’s Royalty Pharma RPRX Stock Holding History

Heartland Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Sell
204,398
-10,000
-5% -$520K 0.51% 70
2026
Q1 		$10.3M Buy
214,398
+409
+0.2% +$17.9K 0.52% 60
2025
Q4 		$8.27M Buy
213,989
+117,436
+122% +$4.48M 0.45% 86
2025
Q3 		$3.41M Buy
+96,553
New +$3.5M 0.18% 170

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Heartland Advisors's RPRX Position: Q2 2026 in Review

Heartland Advisors reduced its Royalty Pharma (RPRX) stake by 4.7% in Q2 2026, selling an estimated $520K and leaving 204,398 shares worth $11.5M. The position accounts for 0.51% of the portfolio, ranked #70.

Heartland Advisors first reported a position in RPRX in Q3 2025 and has held it in 4 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Heartland Advisors held 204,398 shares of Royalty Pharma worth $11.5M as of Q2 2026.
  • Heartland Advisors sold 10,000 Royalty Pharma shares in Q2 2026, an estimated $520K.
  • Royalty Pharma made up 0.51% of Heartland Advisors's portfolio in Q2 2026, its #70 holding.
  • Heartland Advisors first reported a position in Royalty Pharma in Q3 2025 and has held it in 4 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Heartland Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.